Published in Diabetes Care on November 01, 2008
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Sick individuals and sick populations. Int J Epidemiol (1985) 23.44
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 16.62
Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA (2008) 13.69
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (2007) 9.56
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg (1995) 9.02
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia (2006) 8.18
Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol (2007) 7.79
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet (2007) 6.80
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 6.17
Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med (2004) 6.12
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 5.65
Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med (2006) 5.54
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 4.38
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09
Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007) 3.99
Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care (2005) 3.96
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet (2001) 3.60
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76
Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am J Clin Nutr (2006) 2.76
Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care (2002) 2.69
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med (2002) 2.59
Behavioral treatment of obesity. Psychiatr Clin North Am (2005) 2.58
Surgery for severe obesity. N Engl J Med (2004) 2.34
What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol (1997) 2.28
The prediabetic state. A concept of dynamic resistance to a genetic diabetogenic influence. Am J Med (1961) 2.06
Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J (1999) 1.83
Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care (2008) 1.79
Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care (2005) 1.68
Aspirin therapy in diabetes. Diabetes Care (2004) 1.55
Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care (2005) 1.52
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med (2000) 1.51
Sibutramine produces dose-related weight loss. Obes Res (1999) 1.50
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism (2005) 1.39
Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care (2007) 1.24
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care (2008) 1.22
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol (2005) 1.14
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol (2006) 1.12
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab (2002) 1.05
Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care (2005) 1.03
Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest (2005) 1.03
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care (2007) 1.01
Effect of metformin on patients with impaired glucose tolerance. Diabet Med (1999) 1.00
Metabolic syndrome and hyperglycemia: congruence and divergence. Am J Cardiol (2006) 0.96
Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab (2008) 0.95
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care (2003) 0.93
American College Of Endocrinology Pre-Diabetes Consensus Conference: part one. Diabetes Care (2008) 0.81
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract (2011) 4.69
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Is haemoglobin A1c a step forward for diagnosing diabetes? BMJ (2009) 1.82
Premicroalbuminuria in women with polycystic ovary syndrome: a metabolic risk marker. Endocr Pract (2008) 1.51
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract (2011) 1.41
Does A1c consistently reflect mean plasma glucose? J Diabetes (2010) 1.39
Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes (2011) 1.18
Cohort profile: risk evaluation of cancers in Chinese diabetic individuals: a longitudinal (REACTION) study. J Diabetes (2014) 1.15
International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes: response to the International Expert Committee. Diabetes Care (2009) 1.08
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care (2007) 0.95
Approaches to treatment of type 2 diabetes. Diabetes Care (2008) 0.92
Diabetes and cancer--an AACE/ACE consensus statement. Endocr Pract (2013) 0.91
Gestational diabetes mellitus and obesity. Diabetes Care (2010) 0.91
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract (2006) 0.90
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. Endocr Pract (2017) 0.90
American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care (2003) 0.88
Cardiovascular disease and diabetes. Diabetes Care (2003) 0.87
Diabetes and cardiovascular disease. Diabetes Care (2011) 0.86
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract (2015) 0.85
Cardiovascular disease in diabetes. Diabetes Care (2008) 0.85
Diabetic retinopathy. Diabetes Care (2008) 0.84
Comment on: Selvin et al. No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes. Diabetes Care 2013;36:2995-3001. Diabetes Care (2013) 0.83
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract (2013) 0.83
Hypertension in diabetes: treatment considerations. J Clin Hypertens (Greenwich) (2011) 0.83
Approaches to treatment 1: How is type 2 diabetes actually treated? J Diabetes (2015) 0.82
American College Of Endocrinology Pre-Diabetes Consensus Conference: part one. Diabetes Care (2008) 0.81
Diabetic neuropathy. Diabetes Care (2008) 0.81
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2015 EXECUTIVE SUMMARY. Endocr Pract (2015) 0.80
Gut-derived incretin hormones and new therapeutic approaches. Diabetes Care (2004) 0.80
New insights in obesity. Diabetes Care (2002) 0.80
Hemoglobin A1c in diabetes diagnosis: time for caution. Endocr Pract (2010) 0.80
Nonnutritive sweeteners, fructose, and other aspects of diet. Diabetes Care (2011) 0.79
The diabetic foot. Diabetes Care (2008) 0.79
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract (2017) 0.78
Insulin concerns and promises. Diabetes Care (2011) 0.78
American College of Endocrinology Pre-Diabetes Consensus Conference: part three. Diabetes Care (2008) 0.77
The American Diabetes Association's 57th annual advanced postgraduate course: diabetes risk, vitamin D, polycystic ovary syndrome, and obstructive sleep apnea. Diabetes Care (2011) 0.77
Obesity: mediators and treatment approaches. Diabetes Care (2009) 0.77
Type 2 diabetes: uses of thiazolidinediones and insulin. Diabetes Care (2011) 0.77
Fibrate use in diabetes: new concepts. J Diabetes (2011) 0.76
Diabetes and nutrition. Diabetes Care (2002) 0.75
Cardiovascular disease and glycemic treatment. Diabetes Care (2010) 0.75
Bariatric surgery, exercise, and inpatient glycemia treatment: the American Diabetes Association's 57th Annual Advanced Postgraduate Course. Diabetes Care (2010) 0.75
2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts. Diabetes Care (2010) 0.75
Neuropathy, retinopathy, and glucose-lowering treatments. Diabetes Care (2010) 0.75
Tight blood glucose control. Geriatrics (2008) 0.75
Aspects of insulin treatment. Diabetes Care (2010) 0.75
Diabetes treatment and cardiovascular safety. Diabetes Care (2011) 0.75
SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract (2015) 0.75
New treatments for diabetes. N Engl J Med (2007) 0.75
Is there a U-shaped curve of A1c versus mortality? J Diabetes (2012) 0.75
Individualizing therapy: do we have the tools to do it? J Diabetes (2014) 0.75
The Journal of diabetes: continuing the dialogue. J Diabetes (2013) 0.75
Diet and diabetes. Diabetes Care (2004) 0.75
Diabetes: the prototypical non-communicable disease. J Diabetes (2012) 0.75
Diabetes treatment and measures of glycemia. Diabetes Care (2009) 0.75
Good news! J Diabetes (2010) 0.75
Gut hormones and the brain. J Diabetes (2010) 0.75
The 6th Annual World Congress on the Insulin Resistance Syndrome. Diabetes Care (2009) 0.75
AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. Endocr Pract (2017) 0.75
How do we gauge the success of treatment of diabetes? J Diabetes (2012) 0.75
Bone disease, gestational diabetes mellitus, and health care. Diabetes Care (2009) 0.75
Learning from ORIGIN. J Diabetes (2012) 0.75
Advances in sleep research. J Diabetes (2015) 0.75